Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yu-Pei Zhao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5103798410. Sources: OpenAlex.

Their work

Papers
49 (first author 6, last author 36)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2011: 5 papers · 2012: 4 papers · 2013: 9 papers · 2014: 5 papers · 2015: 5 papers · 2016: 5 papers · 2017: 3 papers · 2018: 3 papers · 2019: 4 papers · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 49

  1. Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer. Last author DOI 10.1136/gutjnl-2025-336117↗
  2. Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model. Last author DOI 10.1016/j.canlet.2025.217751↗
  3. Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis. Last author DOI 10.21037/atm-20-5606↗
  4. Pancreatic cancer with ovarian metastases: A case report and review of the literature. Last author DOI 10.12998/wjcc.v8.i21.5380↗
  5. Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2020.00576↗
  6. High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.39800↗
  7. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.02.043↗
  8. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.humpath.2018.11.026↗
  9. Non-invasive detection of pancreatic cancer by measuring DNA methylation of Basonuclin 1 and Septin 9 in plasma. Last author DOI 10.1097/cm9.0000000000000257↗
  10. New Insight into the Role of Exosomes in Pancreatic Cancer. Last author PMID 31308040↗
  11. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.25253↗
  12. High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.prp.2017.11.013↗
  13. Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.4103/0366-6999.247211↗
  14. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Last author DOI 10.1016/j.canlet.2017.02.036↗
  15. Surgeons' knowledge regarding the diagnosis and management of pancreatic cancer in China: a cross-sectional study. Last author DOI 10.1186/s12913-017-2345-6↗
  16. WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ol.2017.5784↗
  17. Expression and Significances of MTSS1 in Pancreatic Cancer. Last author DOI 10.1007/s12253-015-9963-2↗
  18. G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance. Last author DOI 10.1016/j.humpath.2016.06.012↗
  19. Prognostic Impact of Cell Division Cycle Associated 2 Expression on Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/s1001-9294(16)30043-8↗
  20. Advances in understanding the molecular mechanism of pancreatic cancer metastasis. Last author DOI 10.1016/s1499-3872(15)60033-9↗
  21. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. Last author DOI 10.18632/oncotarget.11330↗
  22. Localized Autoimmune Pancreatitis: Report of a Case Clinically Mimicking Pancreatic Cancer and a Literature Review. Last author DOI 10.1097/md.0000000000001656↗
  23. Expression of c-fos was associated with clinicopathologic characteristics and prognosis in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0120332↗
  24. Changes in the Expression of Glucose-regulated Protein 78 in the Occurrence and Progression of Pancreatic Cancer in Mouse Models. Last author DOI 10.3881/j.issn.1000-503x.2015.03.002↗
  25. HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer. Last author PMID 26692947↗
  26. Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer. Last author PMID 26823787↗
  27. N-wasp in pancreatic ductal adenocarcinoma: associations with perineural invasion and poor prognosis. Co-author DOI 10.1007/s00268-014-2500-8↗
  28. The prognostic value of Cyclin B1 in pancreatic cancer. Co-author DOI 10.1007/s12032-014-0107-4↗
  29. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer. First author DOI 10.1016/j.arcmed.2013.10.001↗
  30. Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer. Co-author DOI 10.1016/s1499-3872(14)60272-1↗
  31. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. Last author DOI 10.1371/journal.pone.0092847↗
  32. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer. First author DOI 10.1007/s00268-013-2010-0↗
  33. MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer. First author DOI 10.1007/s11605-013-2230-5↗
  34. Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer. Last author DOI 10.1016/j.canlet.2012.10.039↗
  35. Oligonucleotide microarray identifies genes differentially expressed during tumorigenesis of DMBA-induced pancreatic cancer in rats. Last author DOI 10.1371/journal.pone.0082910↗
  36. Vitamin D status and the risk of pancreatic cancer: a meta-analysis. First author DOI 10.3760/cma.j.issn.0366-6999.20122850↗
  37. [Expression of eukaryotic translation initiation factor 5A2 in pancreatic adenocarcinoma and its correlation with the prognosis]. Last author DOI 10.3881/j.issn.1000-503x.2013.06.009↗
  38. [Expression of mitogen activated protein kinase phosphatase-1 in pancreatic cancer]. Last author DOI 10.3881/j.issn.1000-503x.2013.06.011↗
  39. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer. Last author DOI 10.5754/hge12687↗
  40. [The role of perioperative enteral and parenteral nutrition treatment in pancreatic cancer: a multicenter, prospective randomized controlled trial]. Last author PMID 24444682↗
  41. NOP14 promotes proliferation and metastasis of pancreatic cancer cells. Last author DOI 10.1016/j.canlet.2012.03.010↗
  42. Induction, modulation and potential targets of miR-210 in pancreatic cancer cells. Co-author DOI 10.1016/s1499-3872(12)60168-4↗
  43. Metabolic syndrome components and risk factors for pancreatic adenocarcinoma: a case-control study in China. Last author DOI 10.1159/000341397↗
  44. [Validation of candidate immunogenic membrane antigens of human pancreatic cancer screened by proteomics]. First author PMID 22800753↗
  45. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. First author DOI 10.1016/j.arcmed.2011.01.006↗
  46. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. Last author DOI 10.1016/j.bbrc.2011.02.027↗
  47. Advances in early diagnosis and therapy of pancreatic cancer. Last author DOI 10.1016/s1499-3872(11)60021-0↗
  48. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines. Co-author PMID 21362344↗
  49. [Interpretation of the Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Pancreatic Adenocarcinoma Guideline 2011]. Co-author PMID 22177426↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei You · 31 shared papers, 2011–2025 · strength 2.20
  2. Taiping Zhang · 27 shared papers, 2011–2025 · strength 1.60
  3. Li Zhou · 23 shared papers, 2011–2020 · strength 1.38
  4. Junchao Guo · 15 shared papers, 2013–2020 · strength 0.97
  5. Zhiyong Liang · 12 shared papers, 2015–2020 · strength 0.91
  6. Ming Cui · 3 shared papers, 2019–2026 · strength 0.45
  7. Bingqi Li · 5 shared papers, 2017–2019 · strength 0.42
  8. Menghua Dai · 3 shared papers, 2013–2021 · strength 0.38
  9. Jun Lü · 4 shared papers, 2017–2020 · strength 0.35
  10. Gang Yang · 2 shared papers, 2019–2025 · strength 0.30
  11. Ge Chen · 7 shared papers, 2011–2014 · strength 0.28
  12. Hong Shu · 7 shared papers, 2012–2014 · strength 0.28
  13. Quan Liao · 5 shared papers, 2011–2017 · strength 0.27
  14. Qiaofei Liu · 3 shared papers, 2015–2020 · strength 0.27
  15. Quan Liao · 4 shared papers, 2012–2020 · strength 0.26
  16. Sen Yang · 1 shared paper, 2026 · strength 0.26
  17. Joseph R. Habib · 1 shared paper, 2026 · strength 0.26
  18. Christopher L. Wolfgang · 1 shared paper, 2026 · strength 0.26
  19. Ammar A. Javed · 1 shared paper, 2026 · strength 0.26
  20. Mengyi Wang · 4 shared papers, 2015–2016 · strength 0.24
  21. Wen-Jing Liu · 3 shared papers, 2013–2018 · strength 0.22
  22. Jinxin Tao · 1 shared paper, 2025 · strength 0.21
  23. Jiangdong Qiu · 1 shared paper, 2025 · strength 0.21
  24. Bo Xu Ren · 1 shared paper, 2025 · strength 0.21
  25. Hao Chen · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.